Perspective Therapeutics (CATX) Prepaid Assets (2011 - 2026)
Perspective Therapeutics' (CATX) quarterly Prepaid Assets came in at $4.4 million in Q2 2026, up 5.37% year-over-year from $4.2 million in Q2 2025, and little changed quarter-over-quarter from $4.4 million in Q1 2026.
Analysis
Perspective Therapeutics (CATX) Prepaid Assets (2011 - 2026) Analysis & Trends
Perspective Therapeutics has disclosed Prepaid Assets across 16 years of filings, most recently posting $4.4 million for Q2 2026.
- In Q2 2026, Prepaid Assets rose 5.37% year-over-year to $4.4 million; the TTM figure through Jun 2026 stood at $4.4 million (up 5.37% YoY), while the FY2025 annual figure was $3.6 million, down 11.68% from the prior year.
- Prepaid Assets came in at $4.4 million for Q2 2026 at Perspective Therapeutics, roughly flat from $4.4 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $4.4 million in Q2 2026 to a low of $435000.0 in Q2 2022.
- Average Prepaid Assets over 5 years is $2.2 million, with a median of $1.4 million recorded in 2023.
- Year-over-year, Prepaid Assets slipped 17.2% in 2022 and soared 264.34% in 2024.
- Over 5 years, Prepaid Assets stood at $443000.0 in 2022, then jumped by 155.76% to $1.1 million in 2023, then soared by 264.34% to $4.1 million in 2024, then slipped by 11.68% to $3.6 million in 2025, then climbed by 20.08% to $4.4 million in 2026.
- Per Business Quant data, the three most recent Prepaid Assets figures were $4.4 million in Q2 2026, $4.4 million in Q1 2026, and $3.6 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Perspective Therapeutics | 361.95 Mn | 361.95 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.38 Mn |
| Mar 31, 2026 | 4.37 Mn |
| Dec 31, 2025 | 3.65 Mn |
| Sep 30, 2025 | 4.18 Mn |
| Jun 30, 2025 | 4.16 Mn |
| Mar 31, 2025 | 3.96 Mn |
| Dec 31, 2024 | 4.13 Mn |
| Sep 30, 2024 | 2.11 Mn |
| Jun 30, 2024 | 1.23 Mn |
| Mar 31, 2024 | 1.29 Mn |
| Dec 31, 2023 | 1.13 Mn |
| Sep 30, 2023 | 961,000.00 |
| Jun 30, 2023 | 1.43 Mn |
| Mar 31, 2023 | 1.04 Mn |
| Dec 31, 2022 | 443,000.00 |
| Sep 30, 2022 | 662,000.00 |
| Jun 30, 2022 | 435,000.00 |
| Mar 31, 2022 | 551,000.00 |
| Dec 31, 2021 | 535,000.00 |
| Sep 30, 2021 | 306,000.00 |